Study links GLP1 agonists to reduced risk of severe liver disease in diabetic patients

Ozempic and other GLP1 agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes and chronic liver disease, according to a nationwide study from Karolinska Institutet in Sweden published in the journal Gut.

8MW-2311 by Mabwell Shanghai Bioscience for Solid Tumor: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

December 21, 2023

Study shows mother’s milk proteins and carbs crucial for infant growth, fat less so

Systematic review examines the impact of human milk macronutrients on infant growth, revealing that digestible carbohydrates increase infant weight and milk proteins correlate with increased

November 21, 2023

New approach needed to better prepare and support women during menopause transition, experts say

A new approach to menopause that better prepares and supports women during midlife is needed – going beyond medical treatments, to empower women using high-quality

March 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.